Edward Anders Kolb, MD
Hematology/OncologyInsurance Accepted
- Aetna Better Health FL Medicaid and Healthy Kids
- Aetna Better Health PA Kids HMO
- Aetna HMO
- Aetna HMO/POS/PPO/EPO
- Aetna PPO/POS/EPO
- Amerihealth Caritas Delaware
- Amerihealth Caritas Delaware - Delaware & Chester CTY ONLY
- AMERIHEALTH CARITAS DELAWARE VIP NEXT
- AvMed
- Blue Cross and Blue Shield HMO
- Blue Cross and Blue Shield Non HMO
- Blue Cross Blue Shield Florida Blue Select
- Carefirst MD Community Health Plan Mcaid
- Cigna PPO/EPO/HMO/POS/OPEN ACCESS
- Cigna/Great West HMO EPO POS
- Cigna/Great West PPO
- Community Care Plan Medicaid
- Delaware First Health
- Delaware Medicaid/Diamond State
- Delaware Medicare
- Devon Health Services
- Employers Health Network PPO
- Evolutions Healthcare
- Fidelis Care NJ Medicaid HMO
- First Health Aetna PPO/EPO
- First Health/Affordable PPO
- Florida Medicaid
- Geisinger Health Plan Commercial
- Global Medical Managment DE/PA
- Health First Health Plans
- Health Partners Medicaid/Kidz Partner HMO
- HealthSmart Health Plans PPO
- Highmark Blue Cross Blue Shield of Delaware
- Highmark Blue Cross Blue Shield of Delaware *PA Loc Contiguous to DE*
- Highmark Blue Cross Blue Shield of Delaware *PA Loc NONContiguous to DE*
- Highmark Blue Cross Blue Shield of Pennsylvania
- Highmark Medicaid Health Options
- Horizon Blue Cross Blue Shield of New Jersey
- Independance Blue Cross/Amerihealth/Keystone Health Plan
- Insurance Administrators of America
- INTEGRA Administrative Group (ClaimsBridge)
- Interlink Transplant
- Keystone First Medicaid HMO
- Lifetrac Transplant
- Maryland Medicaid
- Molina Healthcare Medicaid
- Multiplan PPO
- New Jersey Medicaid
- Olympus Managed Healthcare PPO DE/PA
- Olympus Managed Healthcare PPO ORL
- Pennsylvania Medicaid
- Plan Vista/NPPN PPO
- Preferred Healthcare PPO
- Priority Partners John Hopkins
- Private Health Care Systems (PHCS)
- Qualcare HMO/POS/PPO
- Seminole Tribe of Florida
- Simply Healthcare Healthy Kids
- Simply Healthcare Medicaid HMO
- Star Healthcare Network
- Three Rivers Provider Network
- Tricare/Humana Military Health Services/CHAMPVA
- United Healthcare of the Mid-Atlantic
- UPMC Medicaid/CHIP
- US Family Health Plan
- Wellpoint Maryland Medcaid
- Blood and Bone Marrow Transplantation
- Blood Disorders
- Cancer Care
- Leukemia
- Lymphoma
- Neuroblastoma
- Neutropenia
Research Activities
The children we treat need the most powerful, effective therapies right now – not days, weeks, or months from now. So I’m deeply involved in clinical and translational research, actively seeking to learn as much as possible from each child in our care. Our physicians stay up-to-date on the latest research strategies for kids with cancer, because everything we learn will help others in the future.
The focus of our lab is to identify novel therapies for children with cancer. We recognize the challenges that we face: 1) childhood cancer is a rare and orphan disease; 2) it is difficult to complete clinical trials for rare diseases; 3) drug development is focused on malignancies in adults; 4) we need better treatments for children now. To address all these problems, my lab works with a team of investigators at other institutions around the world to identify those therapies most likely to succeed in children and to prioritize them for clinical development. With more than 60 publications resulting in dozens of clinical trials, we have made great progress. Team science is the model that works. We don’t compete, we cooperate and share.
As a member of the Children’s Oncology Group Scientific Council, Chair of the Myeloid Disease committee, member of the Bone Tumor Committee and member of the Young Investigator Committee, I am in a position to maintain a cutting edge and relevant focus in my lab. We are continually taking results from the bench to bedside and back again; asking those research questions that will have the greatest impact on patient care. Our mission is, simply stated, to find better treatments for childhood cancer. Cure is not impossible with the right teams asking the right questions.
Medical Interests
- Bone marrow failure systems
- Graft vs. host disease
- Retinoblastoma
- Transplant for inherited disorders
- Treatment of non-malignant disorders of the bone marrow and immune system
-
Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG; Cancers; (2021).
-
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration; European Journal of Cancer; (2020).
-
Protection against bovine respiratory syncytial virus in calves vaccinated with adjuvanted modified live vaccine administered in the face of maternal antibody; Vaccine; (2020).
-
Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report; Pediatric Blood and Cancer; (2020).
-
Phase I/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: A report from the children's oncology group; Journal of Clinical Oncology; (2020).
-
Morphologic remission status is limited compared to DN flow cytometry: a Children's Oncology Group AAML0531 report; Blood Advances; (2020).
-
Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology; Molecular Therapy - Methods and Clinical Development; (2020).
-
Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium; Pediatric Hematology and Oncology; (2020).
-
Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium; Pediatric Blood and Cancer; (2020).
-
Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring; BMC Medical Genomics; (2020).
-
Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: A report from the Children's oncology group; Journal of Clinical Oncology; (2020).
-
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium; Pediatric Blood and Cancer; (2020).
-
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group; Haematologica; (2020).
-
Aggressive hematopoietic malignancy characterized by biallelic loss of SMARCB1; JCO Precision Oncology; (2020).
-
A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study; Biology of Blood and Marrow Transplantation; (2020).
-
Stability and change in family psychosocial risk over 6 months in pediatric cancer and its association with medical and psychosocial healthcare utilization; Pediatric Blood and Cancer; (2020).
-
Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples; Genomics and Informatics; (2020).
-
p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma; Scientific Reports; (2019).
-
Screening for Family Psychosocial Risk in Pediatric Hematopoietic Stem Cell Transplantation with the Psychosocial Assessment Tool; Biology of Blood and Marrow Transplantation; (2019).
-
Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy; Pediatric Blood and Cancer; (2019).
-
Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group; Cancer Medicine; (2019).
-
Mentors' perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group; Pediatric Blood and Cancer; (2019).
-
A psychosocial clinical care pathway for pediatric hematopoietic stem cell transplantation; Pediatric Blood and Cancer; (2019).
-
Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group; Pediatric Blood and Cancer; (2019).
-
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design; Cell Reports; (2019).
-
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia; Leukemia; (2019).
-
Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials; Pediatric Blood and Cancer; (2019).
-
Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania; Journal of Molecular Diagnostics; (2019).
-
Bone marrow transplant and pediatric multiple myeloma; Pediatric Blood and Cancer; (2019).
-
A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group; Pediatric Blood and Cancer; (2019).
-
Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions (Nature Medicine, (2017), 24, 1, (103-112), 10.1038/nm.4439); Nature Medicine; (2019).
-
Delivery of care consistent with the psychosocial standards in pediatric cancer: Current practices in the United States; Pediatric Blood and Cancer; (2018).
-
Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial; Cancer; (2018).
-
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions; Nature Medicine; (2018).
-
Development of chemotherapy with cell-cycle inhibitors for adult and pediatric cancer therapy; Cancer Research; (2018).
-
Cytotoxicity of zardaverine in embryonal rhabdomyosarcoma from a Costello syndrome patient; Frontiers in Oncology; (2017).
-
CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome; Molecular Therapy - Nucleic Acids; (2017).
-
Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia; Leukemia Research; (2017).
-
Down syndrome and AML: Where do we go from here?; Blood; (2017).
-
Disease characteristics and prognostic implications of cell-surface FLT3 receptor (CD135) expression in pediatric acute myeloid leukemia: A report from the Children's Oncology Group; Clinical Cancer Research; (2017).
-
Recent advances of cell-cycle inhibitor therapies for pediatric cancer; Cancer Research; (2017).
-
The microtubule network and cell death are regulated by an miR-34a/stathmin 1/ßIIITubulin axis; Molecular Cancer Research; (2017).
-
Implementing the psychosocial standards in pediatric cancer: Current staffing and services available; Pediatric Blood and Cancer; (2017).
-
Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada; Pediatric Blood and Cancer; (2017).
-
MicroRNA expression-based model indicates event-free survival in pediatric acute myeloid leukemia; Journal of Clinical Oncology; (2017).
-
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2017).
-
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2017).
-
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program; Pediatric Blood and Cancer; (2016).
-
Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma; Oncotarget; (2016).
-
Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2016).
-
CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML; Blood; (2016).
-
Evaluation of alternative in vivo drug screening methodology: A single mouse analysis; Cancer Research; (2016).
-
Initial Testing (Stage 1) of MK-8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2016).
-
Generation of pediatric leukemia xenograft models in NSG-B2m mice: Comparison with NOD/SCID mice; Frontiers in Oncology; (2016).
-
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma; Pediatric Blood and Cancer; (2016).
-
Vorinostat enhances cytotoxicity of SN-38 and temozolomide in ewing sarcoma cells and activates STAT3/AKT/MAPK pathways; PLoS ONE; (2015).
-
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric Cancer Models in the Pediatric Preclinical Testing Program; Clinical Cancer Research; (2015).
-
Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane<sup>®</sup>) by the Pediatric Preclinical Testing Program (PPTP); Pediatric Blood and Cancer; (2015).
-
Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2015).
-
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673; Pediatric Blood and Cancer; (2015).
-
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2015).
-
Domestic pigs are susceptible to infection with influenza B viruses; Journal of Virology; (2015).
-
Collaborative efforts driving progress in pediatric acute myeloid leukemia; Journal of Clinical Oncology; (2015).
-
Challenges in converting Acute Myeloid Leukemia (AML) genomics into AML clinical trials; Journal of Clinical Oncology; (2015).
-
Acute myeloid leukemia in children and adolescents: Identification of new molecular targets brings promise of new therapies; Hematology (United States); (2015).
-
A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase I Consortium report; Pediatric Blood and Cancer; (2015).
-
Disruption of Annexin II /p11 interaction suppresses leukemia cell binding, homing and engraftment, and sensitizes the leukemia cells to chemotherapy; PLoS ONE; (2015).
-
Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma; PLoS ONE; (2014).
-
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2014).
-
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).
-
Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).
-
Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).
-
Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).
-
Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).
-
Oncolytic viruses for potential osteosarcoma therapy; Advances in Experimental Medicine and Biology; (2014).
-
Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).
-
A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma; Frontiers in Oncology; (2013).
-
Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: Tumor models for cancer drug discovery; Expert Opinion on Drug Discovery; (2013).
-
Outcomes of Allogeneic Hematopoietic cell transplantation in patients with Dyskeratosis Congenita; Biology of Blood and Marrow Transplantation; (2013).
-
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).
-
Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).
-
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).
-
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).
-
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).
-
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).
-
BIRC5 expression is a poor prognostic marker in Ewing sarcoma; Pediatric Blood and Cancer; (2013).
-
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).
-
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).
-
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).
-
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).
-
Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).
-
Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).
-
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling; Pediatric Blood and Cancer; (2012).
-
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).
-
Progress of oncolytic viruses in sarcomas; Expert Review of Anticancer Therapy; (2012).
-
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).
-
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).
-
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).
-
Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).
-
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).
-
Initial testing of lenalidomide by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2011).
-
Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2011).
-
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2011).
-
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer; Cancer Chemotherapy and Pharmacology; (2011).
-
Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts; Cancer; (2011).
-
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2011).
-
Initial testing of the Aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP); Pediatric Blood and Cancer; (2010).
-
Past, present and future of therapies in pediatric sarcomas; Future Oncology; (2010).
-
Moving towards non-invasive assessments of prognosis in osteosarcoma; Pediatric Blood and Cancer; (2010).
-
Intracranial hemorrhage in alloimmune thrombocytopenia: Stratified management to prevent recurrence in the subsequent affected fetus; American Journal of Obstetrics and Gynecology; (2010).
-
Initial testing of topotecan by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).
-
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).
-
Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric preclinical testing program; Molecular Cancer Therapeutics; (2010).
-
R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts; Pediatric Blood and Cancer; (2010).
-
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).
-
Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).
-
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).
-
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).
-
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).
-
Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma; Cancer Chemotherapy and Pharmacology; (2009).
-
Initial testing of Aplidin by the pediatric pre-clinical testing program; Pediatric Blood and Cancer; (2009).
-
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2009).
-
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2009).
-
Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2009).
-
Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo; Clinical Cancer Research; (2009).
-
Development of IGF-IR inhibitors in pediatric sarcomas; Current Oncology Reports; (2009).
-
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).
-
Initial testing of cisplatin by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).
-
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).
-
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).
-
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).
-
Initial testing of dasatinib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).
-
Initial testing of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2008).
-
The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: A case report; Chemotherapy; (2008).
-
Successful outcome with tandem myeloablative chemotherapy and autologous peripheral blood stem cell transplants in a patient with atypical teratoid/rhabdoid tumor of the central nervous system; Journal of Neuro-Oncology; (2008).
-
The pediatric preclinical testing program: Description of models and early testing results; Pediatric Blood and Cancer; (2007).
-
The neuroradiological findings in a case of Revesz syndrome; Pediatric Radiology; (2007).
-
The folate receptor α is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate; Clinical Cancer Research; (2007).
-
Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma; Clinical Cancer Research; (2007).
-
Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia; Obstetrics and Gynecology; (2006).
-
Dickkopf 3 Inhibits Invasion and Motility of Saos-2 Osteosarcoma Cells by Modulating the Wnt-β-Catenin Pathway; Cancer Research; (2004).
-
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults; Journal of Clinical Oncology; (2003).
-
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma; Cancer; (2003).
-
Imatinib Mesylate in Philadelphia Chromosome-Positive Leukemia of Childhood; Cancer; (2003).
-
A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia; Leukemia; (2003).
-
Ecteinascidin-743 inhibits activated but not constitutive transcription; Cancer Research; (2002).
-
The prevalence of TB infection in a population of homeless persons in Philadelphia; Chest; (1996).
- English